全球药房配药市场规模（按配药类型、治疗领域、应用和地区划分）预测

配药药房的市场规模与预测

2024 年全球复合药局市场规模为 115.5 亿美元，预计到 2032 年将达到 180 亿美元，2026 年至 2032 年的复合年增长率为 5.70%。

调配药局是专门的机构，药师可依每位患者的需求，调配订製药物。与大量生产的药物不同，调配药物是透过组合或改变成分来提供特定剂量、配方或给药方式，而这些剂量、配方或给药方式可能在市场上无法取得。对于需要不含特定过敏原、不同药效或需要替代剂型（例如液体或锭剂）的患者来说，这种做法至关重要。

复合药房广泛应用于皮肤科、荷尔蒙补充疗法、小儿科和兽医学等细分医学专科。其个人化治疗能力使其成为解决患者独特医疗挑战的关键。由于人口老化、慢性病发病率上升以及个人化医疗的兴起，复合药物的需求预计将持续增长。随着自动化和品管改进等技术进步，复合药局将在医疗保健领域发挥更大作用，并提供创新解决方案，从而改善患者的治疗效果。

全球药局市场动态

影响全球医药市场的关键市场动态是：

关键市场驱动因素

慢性病发病率上升和个人化医疗趋势日益增长，推动了对复合药物的需求。根据美国疾病管制与预防中心 ( 美国美国至少患有一种慢性疾病，27.2% 的成年人患有多种慢性疾病。慢性病的高发生率催生了对复合药房能够提供的定製药物的需求。

人口老化加剧：人口老化是复方药局市场的主要驱动力，因为老年人通常需要专门的药物。美国人口普查局预测，到2030年，所有婴儿潮世代都将达到65岁或以上，这将增加老年人口的规模，五分之一的居民将达到退休年龄。这种人口结构变化将增加针对老年人需求的复合药物的需求。

FDA认证核可药短缺：药品短缺一直是医疗保健行业的长期问题，这为配药药房填补这一缺口创造了机会。根据 FDA 药品短缺资料库，截至 2021 年，共有 115 种药品短缺。美国卫生系统药剂师协会 (ASHP) 报告称，截至 2021 年 12 月 31 日，共有 211 种药品短缺。这些药品短缺通常会导致医疗保健提供者转向配药药房寻求替代方案。

主要挑战

法规遵循：遵守各种地方、州和联邦法规是最大的挑战之一。药局必须符合FDA和USP等机构制定的标准，这可能需要昂贵的设施升级和持续的培训。不遵守规定可能会导致处罚、声誉受损，甚至倒闭，影响整个业务。

品管：由于成分和配方的差异，确保所配的药物品质一致并非易事。品管不力可能导致患者出现不良反应，甚至导致药物无效。药房必须投资于完善的系统和测试，这不仅会增加出错的风险，还会增加营运成本。

供应链中断：药局依赖全球采购的原料。地缘政治问题、运输延误和供不应求等因素都可能扰乱业务。医药级原料供应有限，可能需要昂贵的替代品，进而影响定价和客户维繫。

主要趋势

定製药物：个人化医疗是一种日益增长的趋势，即根据患者的个人需求定製药物，包括剂型、强度、成分等。随着患者寻求针对大规模生产的药物无法解决的独特医疗状况的更精准治疗，这种趋势将推动成长，从而增加对药房服务的需求。

生物同质性荷尔蒙需求日益增长：生物同质性荷尔蒙补充疗法(BHRT) 正日益流行，尤其是在寻求自然疗法解决荷尔蒙失衡问题的老年人群体中。能够客製化 BHRT 配方的复方药房可以充分利用这个不断增长的市场，提供传统药物无法提供的个人化选择。

更重视儿科和老年护理：儿科和老年患者通常需要具有特定给药方案的客製化药物，例如液体、咀嚼片等。配药药房在製作这些定製配方中发挥着关键作用，随着医疗保健提供者越来越关注针对这些弱势年龄群体的个人化治疗，配药药房的需求不断增长。

目录

第一章 全球医药市场简介

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章全球药局市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

第五章全球药局配药市场（依配药类型）

• 概述
• 无菌製剂
• 非无菌製剂

第六章全球复方药局市场（依治疗领域）

• 概述
• 疼痛管理
• 荷尔蒙补充疗法（HRT）

第七章全球医药市场应用

• 概述
• 动物用药品
• 小儿科

第八章全球医药市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第九章全球配药市场的竞争格局

• 概述
• 各公司市场排名
• 主要发展策略

第十章 公司简介

• Braun Melsungen AG Company
• Cantrell Drug Company
• Fagron
• Fresenius Kabi AG
• Institutional Pharmacy Solutions
• Lorraine's Pharmacy
• PharMEDium Services LLC
• Triangle Compounding Pharmacies

第十一章 重大进展

• 产品发布/开发
• 合併与收购
• 业务扩展
• 伙伴关係与合作

第十二章 附录

• 相关调查

Compounding Pharmacy Market Size And Forecast

Compounding Pharmacy Market size was valued at USD 11.55 Billion in 2024 and is projected to reach USD 18 Billion by 2032, growing at a CAGR of 5.70 % from 2026 to 2032.

A compounding pharmacy is a specialized facility where pharmacists create customized medications tailored to individual patient needs. Unlike mass-produced pharmaceuticals, compounded medications are prepared by combining or altering ingredients to provide specific dosages, formulations, or delivery methods that may not be commercially available. This practice is essential for patients who require medications free from certain allergens, different dosage strengths, or alternative forms such as liquids or creams instead of pills.

Compounding pharmacies are widely used in niche medical fields like dermatology, hormone replacement therapy, pediatrics, and veterinary medicine, where standard medications may not suffice. Their ability to personalize treatments has made them crucial in addressing patient-specific medical challenges. The demand for compounded medications is expected to grow due to an aging population, increasing chronic diseases, and the rise of personalized medicine. With advancements in technology, such as automation and improved quality control, compounding pharmacies are likely to play a greater role in healthcare, offering innovative solutions that enhance patient outcomes.

Global Compounding Pharmacy Market Dynamics

The key market dynamics that are shaping the global compounding pharmacy market include:

Key Market Drivers:

Increasing Prevalence of Chronic Diseases and Personalized Medicine: The rise in chronic diseases and the growing trend towards personalized medicine are driving the demand for compounded medications. According to the Centers for Disease Control and Prevention (CDC), as of 2018, 51.8% of U.S. adults had at least one chronic condition, and 27.2% had multiple chronic conditions. This high prevalence of chronic diseases creates a need for tailored medications that compounding pharmacies can provide.

Growing Aging Population: The aging population is a significant driver for the compounding pharmacy market, as older adults often require specialized medications. The U.S. Census Bureau projects that by 2030, all baby boomers will be older than 65, expanding the size of the older population so that 1 in every 5 residents will be of retirement age. This demographic shift is likely to increase the demand for compounded medications tailored to the needs of older adults.

Shortages of FDA-Approved Drugs: Drug shortages have become a persistent problem in the healthcare industry, creating opportunities for compounding pharmacies to fill the gap. According to the FDA's drug shortages database, as of 2021, there were 115 drugs in shortage. The American Society of Health-System Pharmacists (ASHP) reported even higher numbers, with 211 active drug shortages as of December 31, 2021. These shortages often lead healthcare providers to turn to compounding pharmacies for alternatives.

Key Challenges:

Regulatory Compliance: Compliance with varying local, state, and federal regulations is one of the biggest challenges. Pharmacies must meet standards set by organizations like the FDA and USP. This can involve costly facility upgrades and continuous training. Failure to comply can result in penalties, reputational damage, or even closure, affecting the overall operation.

Quality Control: Ensuring consistent quality in compounded medications is difficult due to variability in ingredients and formulations. Poor quality control can lead to adverse effects or inefficacy in patients. Pharmacies must invest in robust systems and testing, adding operational costs while increasing the risk of errors.

Supply Chain Disruptions: Compounding pharmacies rely on raw materials sourced globally. Any disruptions, such as geopolitical issues, transportation delays, or supply shortages, can hinder operations. Limited availability of pharmaceutical-grade ingredients may result in costly alternatives, affecting pricing and customer retention.

Key Trends:

Customization of Medications: Personalized medicine is a growing trend, where medications are tailored to individual patient's needs, including dosage forms, strengths, and ingredients. This trend drives growth as patients seek more precise treatments for unique medical conditions that cannot be met by mass-produced pharmaceuticals, increasing demand for compounding services.

Rising Demand for Bioidentical Hormones: Bioidentical hormone replacement therapy (BHRT) is gaining popularity, particularly among aging populations seeking natural solutions for hormone imbalances. Compounding pharmacies can create customized BHRT formulations, tapping into this expanding market and offering tailored options that aren't available through conventional pharmaceuticals.

Increased Focus on Pediatric and Geriatric Care: Both pediatric and geriatric patients often require tailored medications in specific dosages or formats, such as liquid forms or chewable tablets. Compounding pharmacies play a crucial role in creating these custom formulations, driving demand as healthcare providers increasingly turn to personalized treatments for these vulnerable age groups.

Global Compounding Pharmacy Market Regional Analysis

Here is a more detailed regional analysis of the global compounding pharmacy market:

North America:

North America, especially the United States, is leading the compounding pharmacy market due to several key factors. One major driver is the rising prevalence of chronic diseases, with the Centers for Disease Control and Prevention (CDC) noting that 60% of adults in the U.S. have at least one chronic condition, and 40% have multiple conditions. This trend creates a substantial demand for personalized medications, which compounding pharmacies can uniquely provide. As the CDC projects that by 2030, 171 million Americans will have multiple chronic conditions, the need for specialized pharmaceutical services is expected to grow significantly.

The aging population in North America is a critical factor fueling demand for compounded medications. The U.S. Census Bureau anticipates that by 2030, one in five residents will be over the age of 65, which will naturally increase healthcare expenditures. The Centers for Medicare & Medicaid Services (CMS) reported a 9.7% growth in healthcare spending in 2020, reaching $4.1 trillion, with projections of $6.2 trillion by 2028.

Persistent drug shortages reported by the FDA are prompting healthcare providers to turn to compounding pharmacies for alternatives. The regulatory environment, particularly through the Drug Quality and Security Act (DQSA) of 2013, has also bolstered market growth by enhancing the legitimacy and safety standards of compounding pharmacies. Combined with a growing trend toward personalized medicine-where 25% of new drugs approved in 2021 were tailored therapies-the landscape is ripe for continued growth in the North American compounding pharmacy market.

Asia Pacific:

The Asia Pacific region is witnessing significant growth in the compounding pharmacy market, primarily driven by the rising burden of chronic diseases. The World Health Organization (WHO) highlights those non-communicable diseases (NCDs) account for 71% of global deaths, with low- and middle-income countries in this region being disproportionately affected. By 2030, the WHO projects that deaths from NCDs in Southeast Asia will rise to 10.4 million annually, up from 8.5 million in 2012. This escalating health crisis creates a substantial demand for personalized medications, which compounding pharmacies are uniquely positioned to supply. The rapidly aging population, expected to more than double from 630 million in 2020 to approximately 1.3 billion by 2050, adds to this demand, especially in countries like Japan, where nearly 38% of the population will be over 65 by 2050.

In addition to health trends, increasing healthcare expenditures in the region are bolstering the compounding pharmacy market. With healthcare spending in East Asia and the Pacific rising from 6.45% of GDP in 2010 to 7.13% in 2019, investment in specialized pharmaceutical services is expected to grow significantly. The Asia Pacific pharmaceutical market is anticipated to reach $385 billion by 2026, creating ample opportunities for compounding pharmacies. The regulatory landscape is also evolving, with countries like Australia implementing new regulations to ensure quality and safety in compounded medications. Drug shortages further enhance the market potential, as healthcare providers increasingly seek alternatives from compounding pharmacies amid significant medicine shortages reported by regulatory bodies.

Global Compounding Pharmacy Market: Segmentation Analysis

The Global is Segmented on the basis of Compounding Type, Therapeutic Area, Application, And Geography.

Compounding Pharmacy Market, By Compounding Type

• Sterile Compounding
• Non-Sterile Compounding

Based on Compounding Type, the market is fragmented into Sterile Compounding and Non-Sterile Compounding. Sterile compounding is dominating the market due to the increasing demand for customized injectable medications, intravenous (IV) therapies, and other sterile formulations required for patients with specific health conditions, such as cancer or chronic diseases. Strict regulatory standards and the need for quality assurance further enhance the prominence of sterile compounding in the healthcare landscape. Non-sterile compounding is rapidly growing as healthcare providers and patients seek personalized oral medications, topical creams, and other formulations tailored to individual needs, particularly in pediatrics and dermatology. The increasing focus on patient-centered care and the rise in chronic conditions that require individualized treatment plans are propelling the demand for both sterile and non-sterile compounding.

• Compounding Pharmacy, By Therapeutic Area
• Pain Management,
• Hormone Replacement Therapy (HRT

Based on Therapeutic Area, the market is divided into Pain Management and Hormone Replacement Therapy (HRT). The compounding pharmacy market is prominently driven by the therapeutic areas of pain management and hormone replacement therapy (HRT), both of which are experiencing significant growth. Pain management is a critical area as the increasing prevalence of chronic pain conditions, such as arthritis and neuropathy, has led to a heightened demand for personalized pain relief options that compounded medications can provide, especially for patients who may not respond well to standard treatments. Hormone replacement therapy is rapidly expanding, particularly among aging populations seeking to manage symptoms of menopause and andropause. Compounding pharmacies can tailor hormone formulations to meet individual patient needs, ensuring optimal efficacy and minimizing side effects. The growing awareness and acceptance of personalized treatment options in both pain management and HRT are driving substantial growth in these segments of the compounding pharmacy market.

Compounding Pharmacy Market, By Application

• Veterinary Medicine
• Pediatrics

Based on Application, the market is segmented into Veterinary Medicine and Pediatrics. The compounding pharmacy market is significantly influenced by the applications in veterinary medicine and pediatrics, with both segments experiencing growing demand. In veterinary medicine, compounded medications are essential for customizing treatments for pets with unique health needs, such as specific dosages or formulations that are not commercially available. The pediatrics segment is expanding as children often require specialized dosages and formulations, such as liquids or flavored medications, to ensure proper administration and compliance. As awareness of the benefits of personalized medicine increases among healthcare providers and pet owners, the demand for compounded medications in these applications is expected to rise.

Compounding Pharmacy Market, By Geography

• North America
• Asia Pacific
• Europe
• Rest of the world
• On the basis of geographical analysis, the Global Compounding Pharmacy Market is classified into North America, Asia Pacific, Europe, and Rest of the world. The global compounding pharmacy market is notably dominated by North America and is rapidly growing in the Asia Pacific region. North America leads due to a high prevalence of chronic diseases, an aging population, and increasing healthcare expenditures, driving demand for personalized medications. The Asia Pacific region is experiencing rapid expansion fueled by the rising burden of chronic diseases, a rapidly aging demographic, and increasing healthcare spending. The region's pharmaceutical market is projected to grow significantly.

Key Players

The "Global Compounding Pharmacy Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Fagron, B. Braun Melsungen AG, Nephron Pharmaceuticals Corporation, Fresenius Kabi, PharMEDium Services, QuVa Pharma, Triangle Compounding Pharmacies, Pencol ii Pharmacy, Smith Drug Company, and Rx3 Compounding Pharmacy. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Compounding Pharmacy Market Recent developments
• In April 2024, Myonex, a global clinical trial supply company, announced that it hadcompleted its acquisition of Saveway Compounding Pharmacy. The acquisition allow Myonex to better supply patients in clinical trials with medication and equipment as needed. It will also help the company expand its clinical trial designs and include direct-to-patient and home healthcare provider capabilities.
• In November 2023, Precision Compounding Pharmacy, a technology-enabled compounding pharmacy that fulfills telemedicine prescriptions, announced that it had received a seed investment from Right Side Capital Management, a technology investment firm. The funds will allow Precision Compounding Pharmacy to enhance its suite of services, broaden its reach, and drive innovation in the pharmacy industry.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL COMPOUNDING PHARMACIES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL COMPOUNDING PHARMACIES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL COMPOUNDING PHARMACIES MARKET, BY COMPOUNDING TYPE

• 5.1 Overview
• 5.2 Sterile Compounding
• 5.3 Non-Sterile Compounding

6 GLOBAL COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA

• 6.1 Overview
• 6.2 Pain Management
• 6.3 Hormone Replacement Therapy (HRT)

7 GLOBAL COMPOUNDING PHARMACIES MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Veterinary Medicine
• 7.3 Pediatrics

8 GLOBAL COMPOUNDING PHARMACIES MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL COMPOUNDING PHARMACIES MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Braun Melsungen AG Company
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Cantrell Drug Company
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Fagron
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Fresenius Kabi AG
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Institutional Pharmacy Solutions
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Lorraine's Pharmacy
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 PharMEDium Services LLC
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Triangle Compounding Pharmacies
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research